Aortic valve stenosis” is an often-overlooked condition and a growing health concern in ageing societies such as Thailand.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the ...

With the aging of the population, aortic stenosis affects a growing number of patients, with a prevalence of 12.4% among persons who are at least 75 years of age, among whom 3.4% have severe ...

Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...

Results from the EARLY TAVR trial — the first randomized, controlled FDA pivotal study designed to determine the best ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Medtronic (NYSE: MDT) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by ...

Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients: Galway, Ireland Tuesday, April 1 ...

Aortic stenosis is a condition where the aortic valve narrows, obstructing blood flow from the heart to the aorta. As a ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

Over 100 patients successfully treated with the DurAVR ® THV, including de novo (first time) aortic stenosis cases, valve-in-valve (ViV) patients and complex anatomies such as bicuspid aortic valve ...